This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ASCO, CHICAGO, IL, USA, 31 May-4 JUNE 2019

Targeting IGF-1/2 with xentuzumab plus enzalutamide in metastatic castration-resistant prostate cancer after progression on docetaxel chemotherapy and abiraterone: Randomized phase II trial results

Syed Hussain, José Pablo Maroto, Miguel Ángel Climent, Diletta Bianchini, Robert Hugh Jones,  Chia-Chi Lin, Shian-Shiang Wang, Emma Dean, Kate Crossley, Laura Schlieker, Thomas Bogenrieder, Johann de Bono

FOR HEALTHCARE PROFESSIONALS ONLY.

 

image